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Sclerosing sweat duct carcinoma (SSDC) is a
rare slow-growing malignant tumor of the sweat
glands that usually occurs in the head and neck
region.1,2 SSDC isoftenmisdiagnosedclinically,which
can result in tumor mismanagement and recurrence.3
Recent literature has shifted in favor of Mohs micro-
graphic surgery (MMS) as the optimal approach for
this type of tumor because of its tissue-sparing effects
and high cure rates.4,5 We present an unusual case of
SSDC of the lower extremity that was successfully
treated with MMS.CASE REPORT
A 59-year-old healthy white man presented with a
3-year history of a slowly enlarging growth over the
right Achilles tendon. The patient thought that this
lesion was a benign callus on his skin and did not
seek immediate treatment. He was otherwise
healthy, reported no trauma to the area, and com-
plained of no constitutional symptoms.
On examination, the patient exhibited a well-
circumscribed 2.5- 3 2.0-cm firm yellow pink tumor
located on the right posterior calf overlying the
Achilles tendon (Fig 1). No lymphadenopathy was
palpable in the right popliteal or inguinal areas.
An incisional skin biopsy found cords and nests of
basaloid and atypical cells with ductal structures
infiltrating a sclerotic dermis (Fig 2). Perineural inva-
sion was present (Fig 3). Immunohistochemical stains
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bryonic antigen. A consensus diagnosis of SSDC was
made.
After the biopsy, magnetic resonance imagingwas
performed to assess the degree of tumor invasion.
No Achilles tendon or bony structure involvement
was noted. This finding excluded the need for
orthopedic surgery and made MMS a viable option
for this patient.
Tumor removal was accomplished with 1 stage of
MMS using 5-mm surgical margins. The final tumor
defect measured 3.5 3 3.8 cm. Because of the high
degree of skin tension, a trilobed transposition flap
was used to close the defect (Fig 4). An Unna wrap
was subsequently applied to assist with healing.
After MMS, the patient was referred to a surgical
oncologist. Findings from a comprehensive workup
were normal, and the patient was able to ambulate in
short order without difficulty. At his 10-month follow-
up appointment, the patient had no clinical evidence
of tumor recurrence. He was subsequently lost to
follow-up despite multiple attempts to contact him.
DISCUSSION
SSDC is a rare malignant tumor first described by
Goldstein in 1982.6 It is thought to be synonymousJAAD Case Reports 2016;2:284-6.
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Fig 1. Sclerosing sweat duct carcinoma. A 2.5-cm pale
yellow tumor over the superior aspect of the right Achilles
tendon.
Fig 2. The carcinoma infiltrates a sclerotic dermis in cords
and solid aggregates with ductal structures present
(56 3 42 mm; 96 3 96 DPI). (Hematoxylin-eosin stain;
original magnification: 3200.)
Fig 3. Tumor shows perineural invasion. (Hematoxylin-
eosin stain; original magnification: 3400.)
Fig 4. Closing of the defect using a trilobed transposition
flap.
JAAD CASE REPORTS
VOLUME 2, NUMBER 4
Harvey et al 285with microcystic adnexal carcinoma6 and is a type of
sweat gland neuroendocrine tumor.
SSDC usually occurs in whites in the fourth
to sixth decade of life and has an equal sex
distribution.5,7 Clinically, it presents as an indurated
nonhealing tumor in which periods of rapid growth
punctuate durations of slow growth.7 Up to 88% of
cases occur in the head and neck area,8 especially on
the left side of the face.9 Although not formally
studied, some authors feel that this may be caused by
a higher incidence of ultraviolet radiation exposure
in this area.2,3 SSDC has also been observed, less
commonly, in the upper extremity, axilla, trunk, and
lower extremity.
Histologically, SSDC comprises cords and nests of
basaloid cells in desmoplastic stroma,1,7 which form
ductal structures of 1 to 2 cell layers thick. Keratin-filled
cysts havealso beenobserved.7 Immunohistochemical
stains with carcinoembryonic antigen, epithelial
membrane antigen, pan-cytokeratin, and p63 help
confirm tumor identification.10,11 Perineural invasionis common4 with up to 80% of lesions having this
finding.1
In the differential diagnosis, one must consider
tumors such as basal cell carcinoma, squamous
cell carcinoma, desmoplastic trichoepithelioma,
metastatic carcinoma,7 and syringoma.4 SSDC has a
misdiagnosis rate of up to 27%.3 Deeper tissue
samplings are helpful to minimize false-negative
findings.2,3
With respect to treatment, there are no random-
ized prospective studies for this type of tumor, but
because there is a slight risk of metastases, the goal
should be to completely remove this malignancy
from the onset. Margins for excision vary from a few
millimeters with MMS to 3 to 5 cm with wide local
excision. No clear set standard for margins has been
reported in the literature. Local recurrence rates with
wide local excision have been reported as high as
40% to 60%.12 Pathologic ‘‘skip areas’’13,14 perineural
invasion,12,15 and the misinterpretation of atypical
epithelioid structures as normal16 are thought to
contribute to this observance. Most SSDC recur-
rences occur within 2 years after treatment,4,16
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surveillance of tumor sites postoperatively is
recommended. Metastasis from SSDC is rare16,18
with one death reported in an immunocompromised
host.12
MMS is the preferred treatment for SSDC,3,12 as
this procedure is found to be a safe, cost effective,
and tissue sparing for tumors that grow by local
invasion.18 Literature on the use of adjuvant
chemotherapy is limited.19 Postoperative radiation
is not recommended to treat this tumor.1,6
With respect to sentinel lymph node biopsy, no
formal guidelines exist for tumor staging. Case reports
have identified a role for sentinel lymph node biopsy
in staging SSDC15; however, further long-term
randomized studies are still needed to determine if
this should be a standard approach to care.CONCLUSION
SSDC is a challenging tumor to diagnose and treat.
It is important to be aware that this malignancy can
develop over the lower extremity and to promptly
perform a biopsy on any calloused growth or
thickening of the skin that does not respond to
conventional treatment.
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